French Immunotherapy Leader To Be Born From OSE Pharma-Effimune Merger
This article was originally published in Scrip
You may also be interested in...
French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.